Spyre Therapeutics Net Worth
Spyre Therapeutics Net Worth Breakdown | SYRE |
Spyre Therapeutics Net Worth Analysis
Spyre Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Spyre Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Spyre Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Spyre Therapeutics' net worth analysis. One common approach is to calculate Spyre Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Spyre Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Spyre Therapeutics' net worth. This approach calculates the present value of Spyre Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Spyre Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Spyre Therapeutics' net worth. This involves comparing Spyre Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Spyre Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Spyre Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Spyre Therapeutics' net worth research are outlined below:
| Spyre Therapeutics had very high historical volatility over the last 90 days | |
| Spyre Therapeutics was previously known as Aeglea Bio Therapeutics and was traded on NASDAQ Exchange under the symbol AGLE. | |
| The company reported the previous year's revenue of 886 K. Net Loss for the year was (338.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Spyre Therapeutics generates negative cash flow from operations | |
| Spyre Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Fairmount Funds Management LLCs Strategic Acquisition in Oruka Therapeutics Inc |
Spyre Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Spyre Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Spyre Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Spyre Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.63 B.Market Cap |
|
Project Spyre Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (0.78) | (0.82) | |
| Return On Assets | (0.99) | (1.04) | |
| Return On Equity | (1.84) | (1.93) |
When accessing Spyre Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Spyre Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Spyre Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Spyre Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spyre Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spyre Therapeutics' management manipulating its earnings.
Evaluate Spyre Therapeutics' management efficiency
Spyre Therapeutics has return on total asset (ROA) of (0.3881) % which means that it has lost $0.3881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9162) %, meaning that it created substantial loss on money invested by shareholders. Spyre Therapeutics' management efficiency ratios could be used to measure how well Spyre Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -1.04. In addition to that, Return On Capital Employed is expected to decline to -0.82. At present, Spyre Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 358.6 M, whereas Non Currrent Assets Other are forecasted to decline to 8,550.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 26.68 | 25.35 | |
| Tangible Book Value Per Share | 26.68 | 25.35 | |
| Enterprise Value Over EBITDA | (0.18) | (0.19) | |
| Price Book Value Ratio | 0.81 | 0.77 | |
| Enterprise Value Multiple | (0.18) | (0.19) | |
| Price Fair Value | 0.81 | 0.77 | |
| Enterprise Value | 44.1 M | 77.9 M |
The strategic initiatives led by Spyre Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 2 K | Return On Equity (0.92) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spyre Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spyre Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spyre Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spyre Therapeutics Corporate Filings
| 19th of November 2024 Other Reports | ViewVerify | |
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Spyre Therapeutics Earnings per Share Projection vs Actual
Spyre Therapeutics Corporate Management
| James JD | Consultant | Profile | |
| Janet MBA | Senior Operations | Profile | |
| Eric McIntyre | Vice Relations | Profile | |
| Deanna MD | Senior Development | Profile | |
| CFE CPA | Vice Controller | Profile | |
| Justin LaFountaine | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.